EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSMMDG00005015568
Gene Symbol: FGFR3
1 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSMMDG00005006211
Gene Symbol: FLT1
1 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSMMDG00005024298
Gene Symbol: FLT4
1 Cross references
193 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSMMDG00005020707
Gene Symbol: LOC115370776
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSMMDG00005016147
Gene Symbol: LOC115367268
3 Cross references
320 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSMMDG00005016660
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSMMDG00005006307
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSMMDG00005019375
Gene Symbol: LOC115353921
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSMMDG00005005810
Gene Symbol: GABRA1
1 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSMMDG00005014434
Gene Symbol: GABRA2
1 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSMMDG00005024591
Gene Symbol: GABRA3
1 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSMMDG00005014374
Gene Symbol: GABRA4
1 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).